Menu: Home :: go to Journal :: switch to Russian :: switch to English
You are here: all Journals and Issues→ Journal→ Issue→ Article

The meaning of fecal M2-pyruvate kinase at dispensary patients with colorectal cancer

Annotation

Literary review with meta-analysis of 17 randomized studies devoted to screening of colorectal cancer is presented. Among them the most sensitive and specific is a method of finding out fecal pyruvate kinase in feces of M2 type. The research on definition of the role of cancerous fecal pyruvate kinase of M2 type among 32 patients with colorectal cancer after surgical and/or complex treatment is carried out. It is shown that in half of cases the concentration of pyruvate kinase at average is 0.52 U/ml. The significant excess in this level is the evidence of the return of the disease.

Keywords

colorectal cancer; treatment; fecal M2 pyruvate kinase; dispensary care

Full-text in one file

Download

DOI

10.20310/1810-0198-2017-22-1-175-182

UDC

616-006.04

Pages

175-182

References

1. Sostoyanie onkologicheskoy pomoshchi naseleniyu Rossii v 2015 godu [The State of Oncology Help to the Russian Population in 2015]. A.D. Kaprin, V.V. Starinskiy, G.V. Petrov (eds.). Moscow, Herzen Moscow Oncology Research Institute – branch of FSBI “National Medical Research Radiology Centre” of Ministry of Health of Russia, 2016, 236 p. (In Russian). 2. Davydov M.I., Aksel' E.M. Statistika zlokachestvennykh novoobrazovaniy 2014 g. [Statistics of malignant tumours in 2014]. Evraziyskiy onkologicheskiy zhurnal – Eurasian Journal of Oncology, 2016, vol. 4, no. 4, pp. 692-879. (In Russian). 3. Dzhemal A., Vineis P., Brey F., Torre L., Forman D. Atlas po onkologii [Atlas in Oncology]. Atlanta, American Oncology Society, 2014, 136 p. (In Russian). 4. Cole S.R. Cancer Downstaging As a Consequence of the Australian National Bowel Cancer Screening Program. WEO Colorectal Cancer Screening Committee, 2012. 5. Halloran S., Pearson S. OC-Sensor DIANA immunochemical faecal occult blood test analytical performance. WEO Colorectal Cancer Screening Committee Meeting, 2012. 6. Kulibakin B.V. Bol'shaya meditsinskaya entsiklopediya [The Big Encyclopedia]. B.V. Petrovskiy (ed.). Moscow, 1976, vol. 5, p. 68. (In Russian). 7. Timofeev Yu.M. Kolorektal'nyy rak: sovremennye aspekty diagnostiki i lecheniya [Colorectal cancer: modern aspects of diagnostics and treatment]. Russkiy meditsinskiy zhurnal – Russian Medical Journal, 2004, vol. 12, no. 11, pp. 653-656. (In Russian). 8. Allison J.E., Tekawa I.S., Ransom L.J., Adrain A.L. A comparison of fecal occult-blood tests for colorectal-cancer screening. N. Engl. J. Med., 1996, vol. 334, pp. 155-159. 9. Imperiale T.F., Ransohoff D.F., Itzkowitz S.H., Turnbull B.A., Ross M.E. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N. Engl. J. Med., 2004, vol. 351, pp. 2704-2714. 10. Lieberman D.A., Weiss D.G. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N. Engl. J. Med., 2001, vol. 345, pp. 555-560. 11. Collins J.F., Lieberman D.A., Durbin T.E. et al. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann. Intern. Med., 2005, vol. 142 (2), pp. 81-85. 12. Mandel J.S. et al. Colorectal cancer mortality: Effectiveness of biennial screening for fecal occult blood. J. Natl. Cancer Inst., 1999, vol. 91, pp. 434-437. 13. Faivre J., Tazi M.A. Fecal occult blood screening ahd reduction of colorectal cancer mortality; a case control study. Br. J. Cancer, 1999, vol. 79, pp. 680-683. 14. WGO Practice Guidelines, 2008. 15. Bertario L. Reducing colorectal cancer mortality by repeated faecaloccult blood test a nested case–control study. Eur. J. Cancer, 1999, vol. 35, pp. 973-977. 16. Duffy M.J. Use of biomarkers in screening for cancer. Tumor Biol., 2011, vol. 32 (suppl. 1), pp. 5-56. 17. Hardcastle J.D. et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet, 1996, vol. 348, pp. 1471-1477. 18. Hewitson P., Glasziou P.P., Irwig L. et al. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database of Systematic Reviews, 2007, no. 1. DOI: 10.1002/14651858.CD001216.pub2. 19. Mandel J.S. et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N. Engl. J. Med., 1993, vol. 328, pp. 1365-1371. 20. Mazurek S., Grimm H., Oehmke M. et al. Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells. Anticancer Res., 2000, vol. 20, pp. 5151-5154. 21. Melo R.F., Stevan F.R., Campello A.P. et al. Occurrence of the crabtree effect in Hela cells. Cell Biochem. Funct., 1998, vol. 16, pp. 99-105. 22. Oremek C.M., Teigelkamp S., Kramer W. et al. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma. Anticancer Res., 1999, vol. 19, pp. 2599-2602. 23. Eigenbrodt E., Kallinowski F., Ott M. et al. Pyruvate kinase and the interaction of amino acid and carbohydrate metabolism in solid tumors. Anticancer Res., 1998, vol. 18, pp. 3267-3274. 24. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol., 2011, vol. 43, pp. 969-980. 25. Wechsel H.W., Petri E., Bichler K.H., Feil G. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res., 1999, vol. 19, pp. 2583-2590. 26. Lüftner D., Mesterharm J., Akrivakis C., Geppert R., Petrides P.E., Wernecke K.D., Possinger K. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res., 2000, vol. 20, pp. 5077-5082. 27. Schneider J., Morr H., Velcovsky H.G., Weisse G., Eigenbrodt E. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases. Cancer Detect. Prev., 2000, vol. 24, pp. 531-535. 28. Kaura B., Bagga R., Patel F.D. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma. J. Obstet. Gynaecol. Res., 2004, vol. 30, pp. 193-196. 29. Ugurel S., Bell N., Sucker A., Zimpfer A., Rittgen W., Schadendorf D. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma. Int. J. Cancer, 2005, vol. 117, pp. 825-830. 30. Ahmed A.S., Dew T., Lawton F.G., Papadopoulos A.J., Devaja O., Raju K.S., Sherwood R.A. M2-PK as a novel marker in ovarian cancer. A prospective cohort study. Eur. J. Gynaecol. Oncol., 2007, vol. 28, pp. 83-88. 31. Kumar Y., Tapuria N., Kirmani N., Davidson B.R. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker. Eur. J. Gastroenterol. Hepatol., 2007, vol. 19, pp. 265-276. 32. Nisman B., Yutkin V., Nechushtan H., Gofrit O.N., Peretz T., Gronowitz S., Pode D. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy. Urology, 2010, vol. 76, pp. 513.e1-513.e6. 33. Ewald N., Schaller M., Bayer M., Akinci A., Bretzel R.G., Kloer H.U., Hardt P.D. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer. Anticancer Res., 2007, vol. 27, pp. 1949-1952. 34. Hardt P.D., Toepler M., Ngoumou B. et al. Fecal pyruvate kinase (ELISA based on c combination of clone 1 and 3 antibodies) for gastric cancer. Anticancer Res., 2003, vol. 23, pp. 851-854. 35. Haug U., Rothenbacher D., Wente M.N., Seiler C.M., Stegmaier C., Brenner H. Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. Br. J. Cancer, 2007, vol. 96, pp. 1329-1334. 36. Koss K., Maxton D., Jankowski J.A. Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention. Colorectal Dis., 2008, vol. 10, pp. 244-248. 37. Tonus C., Neupert G., Sellinger M. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. World J. Gastroenterol., 2006, vol. 12, pp. 7007-7011. 38. Tonus C., Sellinger M., Koss K., Neupert G. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: A meta-analysis. World J. Gastroenterol., 2012, vol. 18 (30), pp. 4004-4011. 39. Ognerubov N.A., Milovanov V.V., Ivannikov A.A., Ezhova E.N. Issledovanie urovnya fekal'noy piruvatkinazy tipa M2 pri nekotorykh zlokachestvennykh novoobrazovaniyakh [The study of the level of fecal pyruvate kinase of M2 type at some malignant tumours]. Vestnik Tambovskogo universiteta. Seriya Estestvennye i tekhnicheskie nauki – Tambov University Reports. Series: Natural and Technical Sciences, 2013, vol. 18, no. 5, pp. 2864-2866. (In Russian). 40. Ognerubov N.A, Ivannikov A.A, Chang V.L. Fekal'naya M2-piruvatkinaza u bol'nykh kolorektal'nym rakom 3 klinicheskoy gruppy [Fecal M2 pyruvate kinase among patients with colorectal cancer of 3 clinical group]. Zlokachestvennye opukholi – Malignant Tumours, 2016, no. 4, p. 157. (In Russian). 41. Shastri Y.M., Naumann M., Oremek G.M., Hanisch E., Rösch W., Mössner J., Caspary W.F., Stein J.M. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Int. J. Cancer, 2006, vol. 119, pp. 2651-2656. 42. Möslein G., Schneider C., Theilmeier A., Erckenbrecht H., Normann S., Hoffmann B., Tilmann-Schmidt D., Horstmann O., Graeven U., Poremba C. Analysis of the statistical value of various commercially available stool tests – a comparison of one stool sample in correlation to colonoscopy. Dtsch. Med. Wochenschr., 2010, vol. 135, pp. 557-562. 43. Turner D., Leach S.T., Mack D., Uusoue K., McLernon R., Hyams J., Leleiko N., Walters T.D., Crandall W., Markowitz J. et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut, 2010, vol. 59, pp. 1207-1212. 44. Haug U., Hundt S., Brenner H. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. Br. J. Cancer, 2008, vol. 99, pp. 133-135. 45. Shastri Y.M., Loitsch S., Hoepffner N., Povse N., Hanisch E., Rösch W., Mössner J., Stein J.M. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study. Am. J. Gastroenterol., 2008, vol. 103, pp. 1496-1504. 46. Mulder S.A., van Leerdam M.E., van Vuuren A.J., Francke J., van Toorenenbergen A.W., Kuipers E.J., Ouwendijk R.J. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. Eur. J. Gastroenterol. Hepatol., 2007, vol. 19, pp. 878-882. 47. Hardt P.D., Mazurek S., Toepler M., Schlierbach P., Bretzel R.G., Eigenbrodt E., Kloer H.U. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br. J. Cancer, 2004, vol. 91, pp. 980-984. 48. Tonus C., Neupert G., Witzel K. The faecal tumour M2-PK screening test for invasive and pre-invasive colorectal cancer: estimated specificity and results as a function of age for a study population of 4854 volunteers. Nowotwory J. Oncol., 2009, vol. 59, pp. 32e-37e. 49. McLoughlin R., Shiel E., Sebastian S., Ryan B., O´Connor H.J., O´Morain C. Tumor M2-PK, a novel screening tool for colorectal cancer. Poster Abstracts and Trade Exhibition Book. NCRI Cancer Conference. London, Callisto, 2005, p. 202. 50. Kloer H.U., Hardt P.D., Schlierbach P., Toepler M. The tumour metabolic marker M2-PK in stool: a new biomarker for colorectal cancer. Journal of Clinical Oncology, 2005, p. 3598. 51. Schmidt C. Wertigkeit der fäkalen Tumour M2 Pyruvate kinase (TuM2-PK) für die Detektion eines kolorektalen Karzinoms: dr. med. sci. diss. abstr. Würzburg, 2009. (In German). 52. Naumann M., Schaum B., Oremek G.M., Hanisch E., Rösch W., Mössner J., Caspary W.F., Stein J. Faecal pyruvate kinase type M2--a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study. Dtsch. Med. Wochenschr., 2004, vol. 129, pp. 1806-1807. 53. Vogel T., Driemel C., Hauser A., Hansmann A., Lange S., Jonas M., Möslein G. Comparison of different stool tests for the detection of cancer of the colon. Dtsch. Med. Wochenschr., 2005, vol. 130, pp. 872-877. 54. Bellutti M., Mönkemüller K., Malfertheiner R. Faecal Tumour M2-pyruvate kinase (M2-PK) as a potential screening parameter for colorectal adenoma and carcinoma: preliminary results. Anticancer Res. Abstract Eur Bridging Meeting. Magdeburg, Attiki, International Institute of Anticancer Research, 2007, pp. 1949-1952. 55. Karl J., Wild N., Tacke M. et al. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein marcers. Clin. Gastroenterol. Hepatol., 2008, vol. 6 (10), pp. 1122-1128.

Received

2017-03-02

Section of issue

Medicine

Для корректной работы сайта используйте один из современных браузеров. Например, Firefox 55, Chrome 60 или более новые.